Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Molecular Mechanisms and Therapeutic Potential of Resolvins in Cancer-Current Status and Perspectives Publisher Pubmed



Tajbakhsh A1 ; Yousefi F2 ; Farahani N3 ; Savardashtaki A1, 4 ; Reiner Z5, 6 ; Jamialahmadi T7 ; Sahebkar A7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Department of Biological Sciences, Faculty of Genetics, Tarbiat Modares University, Tehran, Iran
  3. 3. Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Department of Internal Medicine, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
  6. 6. Polish Mother's Memorial Hospital Research Institute, Lodz, Poland
  7. 7. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Current Medicinal Chemistry Published:2024


Abstract

Resolvins are specialized pro-resolving mediators derived from omega-3 fatty acids that can suppress several cancer-related molecular pathways, including important activation of transcription parameters in the tumor cells and their microenvironment, inflammatory cell infiltration, cytokines as well as chemokines. Recently, an association between resolvins and an important anti-inflammatory process in apoptotic tumor cell clearance (efferocytosis) was shown. The inflammation status or the oncogene activation in-creases the risk of cancer development via triggering the transcriptional agents, including nuclear factor kappa-light-chain-enhancer of activated B cells by generating the pro-in-flammatory lipid molecules and infiltrating the tumor cells along with the high level of pro-inflammatory signaling. These events can cause an inflammatory microenvironment. Resolvins might decrease the leukocyte influx into the inflamed tissues. It is widely ac-cepted that resolvins prohibit the development of debris-triggered cancer via increasing the clearance of debris, especially by macrophage phagocytosis in tumors without any side effects. Resolvins D2, D1, and E1 might suppress tumor-growing inflammation by activation of macrophages clearance of cell debris in the tumor. Resolvin D5 can assist patients with pain during treatment. However, the effects of resolvins as anti-inflammato-ry mediators in cancers are not completely explained. Thus, based on the most recent studies, we tried to summarize the most recent knowledge on resolvins in cancers. © 2024 Bentham Science Publishers.